White Paper

Rational Design & Development Of Long-Acting Injectable Dosage Forms

By Jim Huang, PhD, Founder & CEO, Ascendia Pharmaceuticals

GettyImages-950086574-oral-solid-OSD-pill-tablet-capsule-development

Due to the advantages of parenteral sustained-release drug delivery (also known as long-acting injectables, LAIs), such as reduced toxicity, longer body half-life, reduced dosing frequency, enhanced patient compliance, and overall reduction of medical care cost, different types of sustained-release injectable delivery systems have been introduced to markets, including injectable drug crystal suspensions, liposomes, polymeric microspheres, polymeric in situ gel systems, oil-based injections, implants, etc. The increasing prevalence of chronic disorders, such as schizophrenia, diabetes, cardiovascular diseases, and cancer, growing demand for self-administration and home healthcare, increasing focus on pediatric and geriatric patients, and the increasing demand for minimally invasive surgeries, have further fueled the growth of the LAI drug delivery market.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: